Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiko Pharmaceutical CoTSE:4574 -1.15%64 Debt-to-Equity is 0.03 as of Jun. 2026, which is 86% below its 10-year median of 0.22. GuruFocus rates TSE:4574 with a GF Score™ of 64/100 and a GF Value™ of 円265.54 (Fairly Valued). The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Taiko Pharmaceutical Co ranks better than 89.03% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Taiko Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:
TSE:4574'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.22 Max: 0.48
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Taiko Pharmaceutical Co was 0.48. The lowest was 0.00. And the median was 0.22.
TSE:4574's Debt-to-Equity is ranked better than 89.03% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs TSE:4574: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Taiko Pharmaceutical Co Debt-to-Equity Related Terms
Taiko Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiko Pharmaceutical Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Taiko Pharmaceutical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiko Pharmaceutical Co (TSE:4574) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taiko Pharmaceutical Co and its competitors. This is 86% below median its historical median of 0.22. According to the industry distribution chart, Taiko Pharmaceutical Co ranks #89 out of 811 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Taiko Pharmaceutical Co's Debt-to-Equity too high?
Taiko Pharmaceutical Co's current Debt-to-Equity of 0.03 is 86% below median its 10-year median of 0.22. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Taiko Pharmaceutical Co's value of 0.03 is 89.3% below this industry median. Based on the distribution chart, Taiko Pharmaceutical Co ranks #89 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Taiko Pharmaceutical Co ranks #89 out of 811 companies for Debt-to-Equity. This places Taiko Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Taiko Pharmaceutical Co's value of 0.03 is 89.3% below this benchmark. While the company's 10-year median is 0.22 vs. the industry median of 0.28, Taiko Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiko Pharmaceutical Co's current Debt-to-Equity of 0.03 is 89.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taiko Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiko Pharmaceutical Co's current Debt-to-Equity is 0.03, which is 86% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Fairly Valued. The stock's GF Value™ is 円265.54, compared to a current price of 円257.00 — trading 3.2% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 86% below median its 10-year median of 0.22 and 89.3% below the Drug Manufacturers industry median of 0.28. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円257.00 is trading 3.2% below its estimated GF Value™ of 円265.54.
GuruFocus considers Taiko Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4574:
Debt-to-Equity: 0.03 (86% below median its 10-year median of 0.22)
GF Value™: 円265.54 vs. price of 円257.00 (3.2% below fair value)
Industry Position: 89.3% below the Drug Manufacturers median (#89 of 811)
No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score
Get the complete analysis for TSE:4574
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4574 has been successfully added to your 
